18 completed. 9 Phase 4, 3 Phase 1, 3 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 9 | Completed 9 |
| Phase 1 | 3 | Completed 3 |
| Phase 3 | 3 | Completed 3 |
| Phase 2 | 1 | Completed 1 |
Follow Nateglinide: new trials by email Literature Review of Nateglinide trials Research Report on Nateglinide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Incretin-based Drugs and the Risk of Heart Failure DPP-4 inhibitors, GLP-1 analogs, Insulins - Type 2 Diabetes Mellitus | Completed | Canadian Network for Observational Drug Effect Studies, CNODES | 1499650 | 2014-03-01 | 2016-04-19 | |
| Incretin-based Drugs and Acute Pancreatitis DPP-4 inhibitors, GLP-1 analogs, Insulins - Diabetes Mellitus, Type 2 | Completed | Canadian Network for Observational Drug Effect Studies, CNODES | 1417914 | 2014-03-01 | 2016-11-03 | |
| Incretin-based Drugs and Pancreatic Cancer DPP-4 inhibitors, GLP-1 analogs, Sulfonylureas - Diabetes Mellitus, Type 2 | Completed | Canadian Network for Observational Drug Effect Studies, CNODES | 886172 | 2014-03-01 | 2016-03-14 | |
| A Open-label, Single-dose, 2-Sequence, 2-Period, Crossover Study to Assess Safety and Pharmacokinetics of a Nateglinide/Metformin HCl Combined Tablet Compared With a Nateglinide 120 mg Tablet and Metformin HCl 500 mg Tablet Under Fasting Conditions in Healthy Male Subjects Nateglinide, Nateglinide/Metformin, Metformin - Healthy Volunteers | Phase 1 | Completed | IlDong Pharmaceutical Co Ltd | 40 | 2012-10-01 | 2014-03-17 |
| A Study to Assess Safety and Efficacy of ASP1941 in Combination With Nateglinide in Type 2 Diabetic Patients ipragliflozin, nateglinide - Type 2 Diabetes Mellitus | Phase 3 | Completed | Astellas Pharma Inc | 122 | 2011-01-15 | 2025-05-30 |
| Effects of Nateglinide on Postprandial Glucose Excursion by Restoring Early Phase Insulin Secretion Nateglinide, Acarbose - Diabetes Mellitus, Type 2 | Phase 4 | Completed | Novartis Pharmaceuticals | 103 | 2009-12-01 | 2012-10-19 |
| Effects of Nateglinide vs Acarbose on Postprandial Glucose Fluctuation, Dyslipidemia, and Inflammatory Factors Nateglinide 120 mg, Acarbose 50 mg - Diabetes Mellitus, Type 2 | Phase 4 | Completed | Novartis Pharmaceuticals | 160 | 2009-07-01 | 2012-05-10 |
| Study of the Durability of Glycemic Control With Nateglinide Nateglinide, Glimepiride - Type 2 Diabetes Mellitus | Phase 4 | Completed | Ajou University School of Medicine | 88 | 2009-04-24 | 2017-05-16 |
| Bioequivalence Study of Nateglinide Tablets 120 mg of Dr. Reddy's Laboratories Limited Under Fasting Condition Nateglinide - Healthy | Phase 1 | Completed | Dr. Reddy's Laboratories Limited | 68 | 2007-02-01 | 2010-07-13 |
| The Effects of Nateglinide and Acarbose on the Post-Prandial Glucose Control in Type 2 Diabetic Patients nateglinide, acarbose - Diabetes Mellitus, Type 2 Diabetes Mellitus | Phase 4 | Completed | Inje University | 85 | 2007-01-01 | 2008-03-24 |
| Safety and Efficacy of Nateglinide in Patients With Type 2 Diabetes Already Taking Insulin Glargine, Metformin and/or Pioglitazone or Rosiglitazone Nateglinide - Type 2 Diabetes | Phase 4 | Completed | Novartis Pharmaceuticals | 28 | 2006-11-01 | 2017-02-24 |
| Bioequivalence Study of Nateglinide Tablets 120 mg of Dr. Reddy's Laboratories Limited Under Fed Condition Nateglinide - Healthy | Phase 1 | Completed | Dr. Reddy's Laboratories Limited | 58 | 2004-10-01 | 2010-07-13 |
| Insulin Resistance and Vessel Function After Meals: Does Early Intervention Make a Difference? Nateglinide - Insulin Resistance, Impaired Fasting Glucose | Phase 4 | Completed | Atheline Major-Pedersen | 70 | 2003-06-01 | 2018-12-03 |
| A Pilot Study to Evaluate the Effects of Nateglinide vs. Glibenclamide on Renal Hemodynamics and Albumin Excretion nateglinide - Diabetes Mellitus, Type 2 | Phase 4 | Completed | Novartis Pharmaceuticals | 24 | 2003-05-01 | 2012-04-27 |
| Efficacy and Safety of Nateglinide Treatment in Renal Transplant Recipients Nateglinide - Renal Transplant Recipients, Posttransplant Diabetes Mellitus | Phase 4 | Completed | University of Oslo School of Pharmacy | 15 | 2002-11-01 | 2006-05-10 |
| Insulin Resistance and Central Nervous System (CNS) Function in Type 2 Diabetes pioglitazone, nateglinide, placebo - Insulin Resistance, Type 2 Diabetes Mellitus | Phase 4 | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 140 | 2002-11-01 | 2010-02-15 |
| Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications Valsartan 160 mg + nateglinide 60 mg, Valsartan 160 mg + nateglinide placebo, Nateglinide 60 mg + valsartan placebo - Diabetes Mellitus, Type 2 | Phase 3 | Completed | Novartis Pharmaceuticals | 9306 | 2002-01-01 | 2023-11-08 |
| Nateglinide: a Double Blind Add-on Study With Pioglitazone for Type 2 Diabetic Patients nateglinide - Type 2 Diabetes Mellitus, Diabetes Mellitus, Type II | Phase 2 / Phase 3 | Completed | Astellas Pharma Inc | 2008-03-13 |
Diabetes Mellitus, Type 2 (13) · Insulin Resistance (3) · Diabetes Mellitus (2) · Dyslipidemias (1) · Glucose Intolerance (1) · Heart Failure (1) · Hyperglycemia (1) · Pancreatic Neoplasms (1) · Pancreatitis (1)
Novartis Pharmaceuticals (5) · Canadian Network for Observational Drug Effect Studies, CNODES (3) · Astellas Pharma Inc (2) · Dr. Reddy's Laboratories Limited (2) · Ajou University School of Medicine (1) · Atheline Major-Pedersen (1) · IlDong Pharmaceutical Co Ltd (1) · Inje University (1) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1) · University of Oslo School of Pharmacy (1)
Canada (4) · China (3) · South Korea (3) · United States (3) · Denmark (2) · Japan (2) · Norway (2) · Argentina (1) · Australia (1) · Austria (1) · Belgium (1) · Brazil (1) · Chile (1) · Colombia (1) · Czechia (1)
Pierre Ernst, MD, MSc (3) · Antonio R Pizarro, MD (2) · Christian Torp-Pedersen, MD, DMSc (1) · Jeonghyun Park, MD PhD (1) · Kwan Woo Lee, MD,PhD (1) · Suzanne Craft, PhD (1) · Trond Jenssen, MD, PhD (1)
PMID 18926145, PMID 20002471, PMID 20184589, PMID 20228402, PMID 20228403, PMID 21376417, PMID 23631607, PMID 24322398, PMID 24361242, PMID 24559843, PMID 24861892, PMID 25447626, PMID 25781235, PMID 26275900, PMID 26888382, PMID 27007958, PMID 27479930, PMID 28087508